

Press Release

For Immediate Dissemination

Glenmark announces the Discovery of a novel chemical entity 'GRC 17536', a potential first-in-class molecule globally

- GRC 17536 is a TRPA1 receptor antagonist indicated for pain and respiratory disorders
- The molecule has completed pre-clinical trials and will move into clinical trials in the first quarter of CY-2011
- Glenmark has already filed multiple patent applications for these molecules
- With this announcement, Glenmark has clearly reaffirmed its position globally as the leader in the TRP space

Mumbai August 30, 2010 :Glenmark Pharmaceuticals today announced the discovery of a Novel Chemical Entity(NCE) 'GRC 17536'. The new NCE program is targeting TRPA1 receptor antagonists for pain and respiratory disorders. TRPA1 belongs to Transient Receptor Potential (TRP) family of ion channels, which have generated a lot of interest as pain targets due to their distinguishing role in peripheral and/or central pain signal transmission.

Glenmark has selected a lead molecule named GRC 17536 which is currently finishing up Phase 1 enabling GLP studies. Preclinical studies have been completed and Glenmark plans to file the Phase 1 application in January 2011. This is another potential first-in-class molecule globally for Glenmark

Commenting on this discovery, Glenn Saldanha, CEO & MD, Glenmark Pharmaceuticals Ltd mentioned "We are glad to announce our third novel molecule discovery in the TRP space. Both our earlier TRP molecules i.e. TRPV1 and TRPV3 resulted in outlicensing deals for the company. GRC 17536 which is a TRPA1 receptor antagonist is another potential first-in-class globally and we are encouraged by the results shown by the molecule in animal studies. GRC 17536 is highly selective even when compared with other TRPs and can be administered orally"

Glenmark is now positioned as one of the leading companies engaged in the discovery of novel TRP antagonists. Previously Glenmark has worked on TRPV1 and TRPV3 receptors and was able to successfully bring programs into clinical development. Both of these programs also resulted in out-licensing deals for Glenmark. To date, Glenmark has discovered several distinct scaffolds of highly potent TRPA1 antagonists with drug-like properties and has filed patent applications for these molecules.

GRC 17536, which is Glenmark's lead is a highly potent (< 10nM) TRPA1 antagonist, which is highly selective (> 1000 fold over other TRPs) and orally available. It has proven highly efficacious in treating inflammatory and neuropathic pain in animal models compared to gold standard drugs. It reversed hyperalgesia in vivo models of Freund's complete adjuvant – induced inflammatory and chronic constriction injury (CCI) – induced neuropathic pain with an EC50 of less than 10 mg/kg. In addition, when tested in an in vivo model of asthma, it showed promising effect on airway inflammation, bronchoconstriction and cough. So far, the compound has showed good safety in the safety pharmacology and toxicology studies performed till date. Glenmark believes TRPA1 antagonist into clinical development amidst competition from a number of biotech and Pharma companies globally.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has eight molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain]. The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has twelve manufacturing facilities in four countries and has five R&D centres.

####

For further information, please contact:

Jason D'Souza

Glenmark, Mumbai, India

Tel: [+91 22] 40189919

Email : media@glenmarkpharma.com